00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
14:58 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell and mouse studies suggest inhibiting M. tuberculosis fum could help treat tuberculosis (TB). In M. tuberculosis culture, knockdown of fum decreased growth and viability compared with normal expression. In a mouse model...
19:49 , Jan 13, 2017 |  BC Week In Review  |  Company News

Futura, Stada Arzneimittel deal

Futura granted Stada’s Thornton & Ross Ltd. subsidiary rights to commercialize pain candidate TPR100 in the U.K. Thornton & Ross will submit a regulatory application next half. Futura will receive an undisclosed upfront payment and...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Financial News

Futura Medical completes placing

Futura Medical plc (LSE:FUM), Guildford, U.K.  Business: Drug delivery, Neurology, Genitourinary  Date completed: 2016-10-27  Type: Placing  Raised: L12 million ($14.7 million)  Shares: 21.1 million  Price: 57p  Shares after offering: 120.1 million  Placement agent: N+1 Singer ...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Glyceryl trinitrate: Phase II data

Top-line data from a double-blind, crossover, U.K. pivotal Phase II trial in 232 patients with ED showed that 0.2% topical MED2002 applied immediately before sexual intercourse met the primary endpoint of improving the EF domain...
07:00 , Jul 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis fumarate hydratase (fum); fumarate hydratase (FH)

Infectious disease INDICATION: Tuberculosis In vitro and cell studies identified an acetamide-based fum inhibitor that could help treat tuberculosis (TB). Screening of a small molecule library in enzymatic activity assays identified an acetamide-based compound that...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Glyceryl trinitrate: Completed Phase II enrollment

Futura completed enrollment of 192 patients in a double-blind, placebo-controlled, crossover, European pivotal Phase II trial evaluating >=4 topical applications of 300 mg MED2002 prior to intercourse over 4 weeks. Futura Medical plc (LSE:FUM), Guildford,...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

2Q milestones

2Q milestones Company Product Indication Event Milestone Ablynx N.V. (Euronext:ABLX) ALX-0171 Respiratory syncytial virus (RSV) infection Ph I/IIa data 2Q16 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Nuplazid pimavanserin Parkinson's disease psychosis (PDP) PDUFA date 5/1/16 Acucela Inc....
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Eroxon: Phase III started

Futura began a double-blind, placebo-controlled, crossover, European Phase III trial to evaluate 4 doses of 300 mg topical MED2002 over 4 weeks in 192 patients. Futura Medical plc (LSE:FUM), Guildford, U.K.   Product: Eroxon (...